Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA565187
Title Can Rapamycin Improve Cognitive Problems Caused by Chemotherapy.
Publication Date May 2012
Media Count 7p
Personal Author B. Christy
Abstract Although advances in treatment have increased survival for breast cancer and other common cancers, many challenges remain. Although life-saving, chemotherapy treatments can be very harsh, and unpleasant side effects are common. Some of these side effects are temporary and well-tolerated by patients, while others may be lasting and negatively impact the quality of life during and after treatment. One commonly reported side effect of chemotherapy in breast cancer patients is chemobrain or chemofog , terms used to describe cognitive problems caused by treatment. These cognitive problems can be mild or severe, and may be long-lasting or even permanent in some patients. Problems in thinking, concentration, learning and memory are generally very distressing to patients and survivors and dramatically affect their quality of life. Finding drugs or other treatments which can prevent or alleviate chemotherapy-induced cognitive problems is an important goal which will dramatically impact the lives of cancer patients. Rapamycin is an FDA-approved drug currently used in transplant patients for immunosuppression. Rapamycin and related drugs work by partially inhibiting the activity of the mTOR protein kinase, which regulates virtually every cellular metabolic process. Rapamycin is relatively safe and well-tolerated in human patients. Rapamycin has been shown to have beneficial cognitive effects in a mouse model of Alzheimer s disease and in non-mutant mice as well (Spillman et al, 2010). Therefore, we proposed that rapamycin treatment may help prevent or improve cognitive problems caused by chemotherapy treatments.
Keywords Anatomical models
Breast cancer
Cells
Chemotherapy
Cognition
Drugs
Impact
Learning
Life saving
Memory devices
Patients
Phosphorus transferases
Proteins
Quality
Rapamycin
Safety
Survival(Personnel)
Transplantation


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
92B - Psychology
57T - Psychiatry
Corporate Author Texas Univ. Health Science Center at San Antonio.
Document Type Technical report
Title Note Annual rept. 1 May 2011-30 Apr 2012.
NTIS Issue Number 1304
Contract Number W81XWH-11-1-0233

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader